May 7 |
Halozyme Therapeutics, Inc. (HALO) Q1 2024 Earnings Call Transcript
|
May 7 |
Halozyme Therapeutics (HALO) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
|
May 7 |
Halozyme Therapeutics Q1 2024 Earnings: Misses EPS Estimates but Shows Revenue Growth
|
May 7 |
Halozyme Therapeutics (HALO) Q1 Earnings Beat Estimates
|
May 7 |
Halozyme Therapeutics, Inc. 2024 Q1 - Results - Earnings Call Presentation
|
May 7 |
Halozyme Therapeutics Non-GAAP EPS of $0.79 beats by $0.09, revenue of $195.88M misses by $3.77M
|
May 7 |
HALOZYME REPORTS FIRST QUARTER 2024 FINANCIAL AND OPERATING RESULTS
|
May 7 |
Expert Ratings For Halozyme Therapeutics
|
May 6 |
Halozyme Therapeutics Q1 2024 Earnings Preview
|
May 6 |
FDA accepts Bristol Myers application for injected Opdivo
|